- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML;…
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial analysts.
▪ Solidigm has explored various funding options, including a potential IPO, to finance a new fab in the U.S. to meet growing AI memory demand. ▪ While an IPO was expected to ease investment burdens and expand capacity for shareholder
There are lots of smart home systems that will let you blast your older dumb appliances with infrared to control them. However, many are tied to ugly cloud systems that can frustrate you on a regul…